| Literature DB >> 32780783 |
Moumita Mukherjee1, Srikanta Goswami1.
Abstract
BACKGROUND: The world is going through the critical phase ofEntities:
Mesh:
Substances:
Year: 2020 PMID: 32780783 PMCID: PMC7418985 DOI: 10.1371/journal.pone.0237559
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 6Schematic representation of host RBP-miRNA interactions along with sequence variation in UTR regions of SARS-CoV-2.
Country/ continent wise list of number of SARS-CoV-2 viral sequences used for this study.
| CHINA | 1-Dec-19 | Feb 02-March 01, 2020 | 197 | |
| INDIA | 30-Jan-20 | April 01- April 30, 2020 | 205 | |
| JAPAN | 3-Jan-20 | Data submitted till May 28, 2020 | 123 | |
| THAILAND | 13-Jan-20 | Data submitted till May 28, 2020 | 121 | |
| TAIWAN | 21-Jan-20 | Data submitted till May 28, 2020 | 102 | |
| ITALY | 30-Jan-20 | Data submitted till May 28, 2020 | 109 | |
| SPAIN | 31-Jan-20 | Data submitted till May 28, 2020 | 671 | |
| ENGLAND | 31-Jan-20 | April 01- April 30, 2020 | 2345 | |
| RUSSIA | 31-Jan-20 | April 01- April 30, 2020 | 130 | |
| GERMANY | 27-Jan-20 | Data submitted till May 28, 2020 | 202 | |
| 25-Jan-20 | March 26- April 25, 2020 | 522 | ||
| USA/ PUERTO RICO | 20-Jan-20 | March 21- April 20, 2020 | 3286 | |
| CANADA | 25-Jan-20 | Data submitted till May 28, 2020 | 147 | |
| 26-Feb-20 | February 26- Submitted till May 28, 2020 | 285 | ||
| 14-Feb-20 | February 14- Submitted till May 28, 2020 | 150 | ||
List of host RNA binding proteins as obtained from RBPmap, predicted to bind to 5’-UTR and 3’-UTR of SARS-CoV-2 RNA.
| Sl no. | RNA Binding Protein | Binding site in 3’-UTR | Z-score | p-value |
|---|---|---|---|---|
| 1. | 129-auaauua | 3.633 | 1.40e-04 | |
| 2. | 83- ucugugu | 2.608 | 4.55e-03 | |
| 3. | 154- ugacagg | 2.111 | 1.74e-02 | |
| 4. | 184- ugcag | 2.124 | 1.68e-02 | |
| 5. | 27- acaaac | 2.772 | 2.79e-03 | |
| 6. | 84- cugugug | 2.641 | 4.13e-03 | |
| 7. | 90- ggcuguc | 2.172 | 1.49e-02 | |
| 8. | 220- aucauca | 2.935 | 1.67e-03 | |
| 9. | 199- guuucgu | 1.908 | 2.82e-02 | |
| 1. | 148-uuaguagu | 3.180 | 7.36e-04 | |
| 100- cuaggga | 2.230 | 1.29e-02 | ||
| 2. | 195- acaaaaa | 3.110 | 9.35e-04 | |
| 3. | 173- uuaauag | 2.340 | 9.64e-03 | |
| 4. | 194- gacaaa | 2.858 | 2.13e-03 | |
| 5. | 180- cuucuua | 1.743 | 4.07e-02 | |
| 6. | 197- aaaaaaa | 3.951 | 3.89e-05 | |
| 7. | 113- ccuaua | 1.917 | 2.76e-02 | |
| 115- uauaug | 2.125 | 1.68e-02 | ||
| 8. | 33- acuug | 1.882 | 2.99e-02 | |
| 9. | 64- ccacgcg | 2.086 | 1.85e-02 | |
| 10. | 142- uuaauuu | 1.660 | 4.85e-02 | |
| 11. | 151- guagugc | 2.444 | 7.26e-03 | |
List of host microRNAs predicted by ‘RNA22 v2’ to have binding sites in the 3’-UTR of the viral genome.
| Sl no. | miRNA | SARS-CoV2 3’-UTR Sequence corresponding to Seed region | folding energy (in -Kcal/mol) | p value |
|---|---|---|---|---|
| 1. | hsa_miR_25_5p | -15.40 | 3.3E-1 | |
| 2. | hsa_miR_105_5p | -13.20 | 3.3E-1 | |
| 3. | hsa_miR_210_3p | -17.80 | 2.24E-1 | |
| 4. | hsa_miR_9_5p | -14.82 | 3.3E-1 | |
| 5. | hsa_miR_34b_5p | -19.40 | 3.3E-1 | |
| 6. | hsa_miR_196b_5p | -16.60 | 3.3E-1 | |
| 7. | hsa_miR_1293 | -19.90 | 2.24E-1 | |
| 8. | hsa_miR_2116_5p | -14.90 | 3.3E-1 | |
| 9. | hsa_miR_323b_5p | -19.70 | 3.3E-1 | |
| 10. | hsa_miR_4497 | -16.10 | 2.24E-1 | |
| 11. | hsa_miR_4659b_3p | -18.80 | 3.3E-1 | |
| 12. | hsa_miR_4757_5p | -20.90 | 2.24E-1 |
List of supporting experimental evidences validating our findings.
| Sl no. | Expression status/ Function in Lungs/ Relationship to Inflammation and Fibrosis/ Viral infection | References | |
|---|---|---|---|
| 1. | CUG-BP | Upregulated in Lung Cancer/ inflammation | [ |
| CUGBP1 Stimulates Human Lung Tumor Growth | [ | ||
| Overexpression of CUGBP1 is associated with the progression of non-small cell lung cancer | [ | ||
| CUG-binding Protein 1 Regulates HSC Activation and Liver Fibrogenesis | [ | ||
| Exercise, Skeletal Muscle and Inflammation: ARE-binding Proteins as Key Regulators in Inflammatory and Adaptive Networks | [ | ||
| 2. | TARDBP | Upregulated in inflammation | [ |
| Facilitation of viral pathogenesis | [ | ||
| 3. | RBMS3 | RBMS3 is a novel Tumour suppressor in Lungs squamous cell carcinoma, and its downregulation facilitates development and progression of LSCC. | [ |
| RBMS3 is upregulated by chronic inflammation and Fibrosis | [ | ||
| 4. | HNRNPA1 | Knockdown of HNRNPA1 Inhibits Lung Adenocarcinoma Cell Proliferation Through Cell Cycle Arrest at G0/G1 Phase | [ |
| Upregulated in inflammation | [ | ||
| SARS-CoV RNA synthesis and turnover regulation | [ | ||
| 5. | SRSF5 | Expression upregulated by viral infection | [ |
| Upregulated by Host-viral interaction | [ | ||
| Upregulated by intracellular stress | [ | ||
| Upregulated in Lung inflammation/ Cancer | [ | ||
| 1. | miR-34b-5p | Upregulated in mouse model of Lungs inflammation and fibrosis. | [ |
| Upregulated in inflammation | [ | ||
| 2. | miE-9-5p | High expression level in normal Lungs tissue. Further overexpressed in NSCLC/ lung inflammation | [ |
| 3. | miR-3664-5p | No report of detectable expression in normal Lungs tissue or in pathogenic condition | |
| Involved in inflammation/ tumorigenesis associated with breast cancer | [ | ||
| 4. | miR-4701-3p | Upregulated in LUAD/ lung inflammation and very less amount of expression in normal Lungs tissue | [ |